<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379808</url>
  </required_header>
  <id_info>
    <org_study_id>06011312</org_study_id>
    <secondary_id>AHA0615253B</secondary_id>
    <nct_id>NCT00379808</nct_id>
  </id_info>
  <brief_title>Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease</brief_title>
  <official_title>Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a particular substance involved in
      inflammation, called leukotrienes, is involved in causing heart disease to occur or to
      progress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The focus of this study is to better understand why some adults develop heart disease and
      others do not. There are many known factors which play a role in causing heart disease, such
      as diet and lifestyle. Also, we know that inflammation, a process in the body which causes
      painful joints in arthritis or swelling at a site if injury, also contributes to heart
      disease. In particular, we will address whether leukotrienes, a component of inflammation, is
      involved in promoting heart disease. We will study this by giving subjects at high risk for
      heart disease a drug called montelukast which causes leukotrienes to have a reduced effect in
      the body. In addition for comparison, we will give other subjects a placebo for the same
      amount of time. These subjects will then be crossed-over and will receive either montelukast
      or placebo depending on which treatment they received first. We will compare these subjects
      using blood tests to see if subjects who take montelukast show signs of less inflammation
      caused by early heart disease as compared to subjects who do not.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High-sensitivity C-reactive Protein</measure>
    <time_frame>1 month</time_frame>
    <description>measured in a CLIA clinical laboratory facility (Quest Diagnostics, Tampa, FL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL)-Cholesterol</measure>
    <time_frame>1 month</time_frame>
    <description>Lipid levels were determined at a clinical laboratory (Quest Diagnostics)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 lactose-containing capsule daily for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 montelukast 10 mg tablet (masked by capsule) daily for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>10 mg tablet (masked by capsule) daily for 1 month</description>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 lactose-containing capsule daily for 1 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Current hypertension (blood pressure &gt; 140/90 mmHg) or current use of anti-hypertensive
        medications AND

        Exclusion Criteria:

          -  Current use of lipid-lowering medications

          -  Current use of montelukast

          -  Poorly controlled hypertension, where systolic blood pressure is greater than 160 or
             diastolic blood pressure is greater than 100

          -  Use of steroid drugs, non-steroidal anti-inflammatory drugs or other anti-inflammatory
             medications in the two weeks prior to enrollment. (low dose aspirin ( &lt; 325 mg) is OK,
             but indication must be cardiovascular)

          -  Current recreational drug use

          -  Other cardiovascular disease or previous cardiovascular event. These include:

          -  history of angina pectoris

          -  history of heart failure

          -  presence of a cardiac pacemaker

          -  history of myocardial infarction

          -  previous revascularization procedure

          -  history cerebrovascular disease including stroke and transient ischemic attack

          -  Pregnancy or lactation

          -  Diabetes mellitus

          -  Lactose intolerance

          -  Contraindications to montelukast therapy

          -  Alcoholism

          -  Known hepatic disease

          -  Existing chronic obstructive pulmonary disease, asthma, allergic rhinitis

          -  Active chronic immune, infectious, neoplastic or inflammatory diseases requiring
             therapy (such as active Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV))

          -  Immunosuppressant therapy or known immunosuppression due to disease high density
             lipoprotein (HDL) &lt; 40 mg/dL (although this would be a risk factor for heart disease,
             because of preliminary data which indicates that montelukast may lower HDL levels, we
             will exclude patients with abnormally low HDL from study)

          -  Other criteria at investigator discretion that are deemed to make the subject a poor
             candidate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie A Johnson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Family Practice Medical Group Clinic</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <results_first_submitted>February 14, 2012</results_first_submitted>
  <results_first_submitted_qc>June 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2012</results_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>montelukast</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited based on flyers posted in public places, through recontact of patients in previous studies, and patients cared for in a family medicine clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Montelukast</title>
          <description>Patients were randomized in a crossover design to placebo or montelukast. Patients int this randomization arm received 4 weeks of placebo then 4 weeks of montelukast. There was no washout between crossover</description>
        </group>
        <group group_id="P2">
          <title>Montelukast Then Placebo</title>
          <description>Patients were randomized in a crossover design to placebo or montelukast. Patients in this arm got montelukast for 4 weeks and then placebo for 4 weeks. There was no washout period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention Period 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Period 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Patients were randomized in a crossover design, but baseline characteristics were presented for all participants. Likewise data are not separated by order of treatment because there were no order effects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>All study participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>High-sensitivity C-reactive Protein</title>
        <description>measured in a CLIA clinical laboratory facility (Quest Diagnostics, Tampa, FL)</description>
        <time_frame>1 month</time_frame>
        <population>based on patients who completed the entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein</title>
          <description>measured in a CLIA clinical laboratory facility (Quest Diagnostics, Tampa, FL)</description>
          <population>based on patients who completed the entire study</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.6" upper_limit="5.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical power was calculated using G*Power (Dusseldorf, Germany). Based on previously observed effects of statin drugs on hsCRP levels, 22 subjects provided 80% power to detect a moderate effect on hsCRP levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon sign rank test</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein (HDL)-Cholesterol</title>
        <description>Lipid levels were determined at a clinical laboratory (Quest Diagnostics)</description>
        <time_frame>1 month</time_frame>
        <population>those completing entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (HDL)-Cholesterol</title>
          <description>Lipid levels were determined at a clinical laboratory (Quest Diagnostics)</description>
          <population>those completing entire study</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="46" upper_limit="68"/>
                    <measurement group_id="O2" value="50" lower_limit="45" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that montelukast does not affect HDL. Not powered for this endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Wilcoxon sign rank</method>
            <param_type>percent difference</param_type>
            <param_value>3.8</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Triglycerides</title>
        <description>measured by a clinical laboratory; Quest Laboratories</description>
        <time_frame>1 month</time_frame>
        <population>those completing the entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>measured by a clinical laboratory; Quest Laboratories</description>
          <population>those completing the entire study</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="75" upper_limit="129"/>
                    <measurement group_id="O2" value="104" lower_limit="73" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that montelukast does not affect triglycerides. The study was not powered to this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>wilcoxon sign rank</method>
            <param_type>percent difference</param_type>
            <param_value>7.4</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Monocyte Chemotactic Protein-1 (MCP-1)</title>
        <description>biomarker was measured by enzyme-linked immunosorbant assay (ELISA)</description>
        <time_frame>1 month</time_frame>
        <population>those who completed the entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte Chemotactic Protein-1 (MCP-1)</title>
          <description>biomarker was measured by enzyme-linked immunosorbant assay (ELISA)</description>
          <population>those who completed the entire study</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="72" upper_limit="105"/>
                    <measurement group_id="O2" value="94" lower_limit="77" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis is that montelukast does not affect MCP-1. Study not powered to the biomarker.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Wilcoxon</method>
            <param_type>percent difference</param_type>
            <param_value>11.9</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin 1 Receptor Antagonist (IL1ra)</title>
        <description>IL1ra was determined by enzyme-linked immunosorbant assay (ELISA)</description>
        <time_frame>1 month</time_frame>
        <population>all participants who completed the entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 1 Receptor Antagonist (IL1ra)</title>
          <description>IL1ra was determined by enzyme-linked immunosorbant assay (ELISA)</description>
          <population>all participants who completed the entire study</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" lower_limit="400" upper_limit="828"/>
                    <measurement group_id="O2" value="587" lower_limit="429" upper_limit="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis is that montelukast does not affect IL1ra.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>wilcoxon sign rank test</method>
            <param_type>percent difference</param_type>
            <param_value>13.3</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Epithelial Cell-derived Neutrophil-activating Peptide 78 (ENA-78)</title>
        <description>biomarker determined by enzyme-linked immunosorbant assay.</description>
        <time_frame>1 month</time_frame>
        <population>those completing the entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is all participants who received placebo, whether in first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Cell-derived Neutrophil-activating Peptide 78 (ENA-78)</title>
          <description>biomarker determined by enzyme-linked immunosorbant assay.</description>
          <population>those completing the entire study</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631" lower_limit="441" upper_limit="1190"/>
                    <measurement group_id="O2" value="527" lower_limit="175" upper_limit="1060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis is that montelukast does not affect ENA-78. The study is not powered to this biomarker</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>wilcoxon sign rank</method>
            <param_type>percent difference</param_type>
            <param_value>16.5</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>This is all participants who received placebo, whether in first or second intervention</description>
        </group>
        <group group_id="E2">
          <title>Montelukast</title>
          <description>This is all patients who received montelukast, whether in the first or second intervention period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because there were no order effects, the placebo groups were combined and the montelukast groups were combined. Therefore results from each of these are not reported by arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Julie Johnson, PI</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-6007</phone>
      <email>johnson@cop.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

